The Paris Stock Exchange rose slightly (+0.09%) on Monday in the first exchanges, continuing the momentum of a start to the year with a bang thanks to the drop in the threat of inflation and the economic reopening of China. .
The star CAC 40 index rose 5.86 points to 6,866.91 points around 9:25 a.m., after a stable opening. On Friday, it ended up 1.47% at 6,860.95 points, the highest since February 18, 2022.
Over the week, it rose by 5.98%, a performance not seen since November 2020, when the announcement of the effectiveness of vaccines against Covid-19 had restored optimism to world markets.
The Parisian coast was delighted with the drop in inflationary pressure, with good figures in France and Germany at the start of the week, then the slowdown in the rise in the average hourly wage in the United States on Friday.
The data of the week feed those who think that the US Federal Reserve will be less tough in the coming months, according to John Plassard, investment specialist at Mirabaud.
A speech by Fed Chairman Jerome Powell on Tuesday and the publication on Thursday of the CPI inflation indicator for December in the United States will give them new indications.
So far so good… Can this last?, wonder the analysts at Banque Postale AM, believing that it is still too early to follow the conclusions drawn by the markets from the latest indicators.
Canal+ recovers OSC
The audiovisual group Canal+ (owned by Vivendi, -0.19% to 38.71 euros) will acquire OCS, the package of pay channels from the telecommunications operator Orange (-1.11% to 9.78 euros), as well as its subsidiary co-production of films and series, they announced Monday in a joint press release.
The amount of the transaction is not specified. But according to the newspaper Les Echos, for once, it is the seller, that is to say Orange, who pays the Canal+ buyer money. Indeed, OCS, launched in 2008 and which has some 3 million subscribers, is indebted and in losses.
Retreat : save by paying less tax. 13 contracts compared
Ipsen buys an American biotech
Ipsen, the third French pharmaceutical laboratory, will buy the American biotech Albireo, specializing in liver disease, for an amount of 952 million dollars (891 million euros), he announced in a press release on Monday.
The transaction should have a dilutive effect on the operating result of Ipsen’s activities until the end of 2024, specifies the group. It should be concluded by the end of the first quarter of 2023. The stock yielded 0.29% to 101.90 euros.
Plastic: Danone sues
NGOs want a judge to force the French multinational yogurt and water bottles Danone (-1.06% 49.11 euros) to overcome its addiction to plastic which often fails in nature, in a summons consulted Monday by the AFP.